ODAIA Strengthens Leadership with Pharma and AI Experts to Drive Growth and Market Expansion
In a significant move to bolster its market presence and respond to escalating customer demands, ODAIA has announced the expansion of its leadership team with the addition of seasoned professionals. The company has appointed Andrew Gunn as Chief Commercial Officer and Jacqueline Markle as Vice President of Pharma Technical Strategy, both bringing a wealth of experience from the life sciences and technology sectors, including a combined total of over 40 years in commercial operations and data science.
Andrew Gunn will oversee the implementation and market adoption of ODAIA's innovative AI platform. His extensive career spans more than 20 years, during which he developed significant expertise in sales effectiveness, patient engagement, and information management. Before joining ODAIA, he held key leadership positions at IQVIA and was instrumental in forming executive relationships and launching new offerings into the market.
On the other hand, Jacqueline Markle will focus on turning predictive intelligence into actionable strategies for commercial teams. With a background in pharma and biotech that entails experience in commercial data science and patient-prediction modeling, Jacqueline previously worked in senior roles at AstraZeneca and Sage Therapeutics. Her insights will be crucial as ODAIA seeks to empower companies to engage healthcare professionals (HCPs) effectively, particularly in identifying eligible patient groups and enhancing timely communications.
Philip Poulidis, CEO and co-founder of ODAIA, shared optimism regarding this strategic expansion, stating, "Andrew and Jackie join ODAIA at a pivotal moment as pharma companies face mounting pressure to identify the right patients faster and engage healthcare professionals more effectively." He emphasized that their extensive knowledge of commercial challenges paired with proven success in deploying transformative technology solutions will be vital for ODAIA's growth.
The integration of AI into pharma commercial operations marks a notable shift and reflects how companies can better connect their therapies with patients. Gunn commented on the significance of this transition, noting that ODAIA's approach allows organizations to glean actionable insights from data directly within their existing workflows. This capability is designed to overcome the longstanding issue of translating strategic intentions into practical actions on the ground.
Recent advancements in artificial intelligence and predictive analytics grant pharma entities the tools to engage with HCPs sooner and more effectively, ultimately speeding up therapeutic delivery to patients. Markle pointed out the importance of agility in this domain, particularly in therapeutic areas where timely insights significantly enhance the quality of life for patients.
Through ODAIA's platform, companies can harness customer data to produce predictive insights that guide their commercial strategies, leading to more efficient HCP engagements. The results have shown promising outcomes, with partners reporting an average increase of 7-14% in new patients starting their therapies compared to those using other systems.
As ODAIA continues to refine its capabilities and build stronger partnerships within the pharmaceutical sector, the ongoing contributions from its new leadership members are anticipated to drive further innovation. This expansion not only signifies ODAIA's commitment to enhancing commercial efficiency across the industry but also represents its aspiration to be at the forefront of integrating AI into the life sciences domain. For those interested in exploring ODAIA's powerful platform in action, a demo video is available on their website.
About ODAIA:
ODAIA stands as a prominent AI entity dedicated to establishing the Customer Science Cloud for the pharmaceutical industry. Renowned biopharmaceutical companies, including three of the top 15 globally recognized organizations, utilize ODAIA's cloud solutions to refine their commercial engagement strategies through predictive omnichannel intelligence. The company’s offerings include machine-learning-powered territory targeting, tailored call lists, and real-time analytics embedded within current CRM workflows. Discover more about ODAIA by visiting their website or following their updates on LinkedIn.
Andrew Gunn will oversee the implementation and market adoption of ODAIA's innovative AI platform. His extensive career spans more than 20 years, during which he developed significant expertise in sales effectiveness, patient engagement, and information management. Before joining ODAIA, he held key leadership positions at IQVIA and was instrumental in forming executive relationships and launching new offerings into the market.
On the other hand, Jacqueline Markle will focus on turning predictive intelligence into actionable strategies for commercial teams. With a background in pharma and biotech that entails experience in commercial data science and patient-prediction modeling, Jacqueline previously worked in senior roles at AstraZeneca and Sage Therapeutics. Her insights will be crucial as ODAIA seeks to empower companies to engage healthcare professionals (HCPs) effectively, particularly in identifying eligible patient groups and enhancing timely communications.
Philip Poulidis, CEO and co-founder of ODAIA, shared optimism regarding this strategic expansion, stating, "Andrew and Jackie join ODAIA at a pivotal moment as pharma companies face mounting pressure to identify the right patients faster and engage healthcare professionals more effectively." He emphasized that their extensive knowledge of commercial challenges paired with proven success in deploying transformative technology solutions will be vital for ODAIA's growth.
The integration of AI into pharma commercial operations marks a notable shift and reflects how companies can better connect their therapies with patients. Gunn commented on the significance of this transition, noting that ODAIA's approach allows organizations to glean actionable insights from data directly within their existing workflows. This capability is designed to overcome the longstanding issue of translating strategic intentions into practical actions on the ground.
Recent advancements in artificial intelligence and predictive analytics grant pharma entities the tools to engage with HCPs sooner and more effectively, ultimately speeding up therapeutic delivery to patients. Markle pointed out the importance of agility in this domain, particularly in therapeutic areas where timely insights significantly enhance the quality of life for patients.
Through ODAIA's platform, companies can harness customer data to produce predictive insights that guide their commercial strategies, leading to more efficient HCP engagements. The results have shown promising outcomes, with partners reporting an average increase of 7-14% in new patients starting their therapies compared to those using other systems.
As ODAIA continues to refine its capabilities and build stronger partnerships within the pharmaceutical sector, the ongoing contributions from its new leadership members are anticipated to drive further innovation. This expansion not only signifies ODAIA's commitment to enhancing commercial efficiency across the industry but also represents its aspiration to be at the forefront of integrating AI into the life sciences domain. For those interested in exploring ODAIA's powerful platform in action, a demo video is available on their website.
About ODAIA:
ODAIA stands as a prominent AI entity dedicated to establishing the Customer Science Cloud for the pharmaceutical industry. Renowned biopharmaceutical companies, including three of the top 15 globally recognized organizations, utilize ODAIA's cloud solutions to refine their commercial engagement strategies through predictive omnichannel intelligence. The company’s offerings include machine-learning-powered territory targeting, tailored call lists, and real-time analytics embedded within current CRM workflows. Discover more about ODAIA by visiting their website or following their updates on LinkedIn.
Topics Business Technology）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.